Posted by Michael Wonder on 31 Jul 2023
Schedule of Pharmaceutical Benefits - 1 August 2023
1 August 2023 - The August 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The August issue of the Schedule includes a few major new/revised listings:
- Enzalutamide (Xtandi) - new indication
- Eptinezumab (Vyepti) - new medicine
- Lanreotide acetate (Mytolac) - new formulation
- Mifepristone with misoprostol (MS-2 Step) - restriction change
- Tofacitinib citrate (Xeljanz) - new indication
- Trabectedin (Yondelis) - new medicine
- Upadacitinib monohydrate (Rinvoq) - new indication
